

# The Role of Rare Molecular Drivers in Cancer Care

A GUIDE TO  
PERSONALIZED  
MEDICINE IN  
RET POSITIVE  
TUMORS



# Faculty and Patient



**Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP**  
Adult Oncology Nurse Practitioner for Thoracic Malignancies  
Abramson Cancer Center  
University of Pennsylvania Medical Center  
Advanced Senior Lecturer  
University of Pennsylvania School of Nursing  
Philadelphia, Pennsylvania



**Qiushi "Martin" Zhang**  
Patient

# Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

## **Planners:**

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP—has disclosed she is a consultant for AstraZeneca.

## **Authors/Presenters:**

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP—has disclosed she is a consultant for AstraZeneca.

Qiushi “Martin” Zhang—has no relevant financial relationships to disclose in relation to the content of this activity.

# Special Thanks!

Presented by



Supported through an independent educational grant from Lilly.

# Accreditation

This activity is approved for up to 1.0 ANCC contact hour.



Scan QR code above to complete CE request form.

# Learning Objectives

- Review how molecular drivers can cause tumor proliferation and appraise the importance of appropriate biomarker testing for various tumor types to guide treatment decisions both at diagnosis and upon progression.
- Appraise the latest testing modalities, such as next-generation sequencing (NGS) and liquid biopsy, to identify molecular drivers in various malignancies, focusing on current molecular testing guideline recommendations.
- Evaluate latest clinical data regarding the efficacy and safety of targeted therapies for the treatment of RET-positive tumors in various malignancies, such as NSCLC and thyroid carcinoma, and discuss the unique toxicities encountered with these drug therapies.
- Using a patient-incorporated approach, analyze strategies the oncology nurse can utilize to increase the use of molecular testing guidelines in practice, mitigate barriers to recommended testing, optimize treatment, prevent and treat adverse events, and collaborate with other members of the oncology care team to improve patient outcomes.